Health Trials

Clinical trials

8

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease

The purpose of this study is to evaluate the efficacy and safety of BHV-1300 in adult participants with Graves' disease who are actively hyperthyroid

Participants needed: 300
Trial details
Phase: Phase 3Age: 18-70Biological sex: AllType: InterventionalSponsor: Biohaven Therapeutics Ltd.Updated: Jun 30, 2026Locations: 5
Eligibility criteria

Participants must have serologically confirmed Graves' disease as documented by... [+1]

History of hyperthyroidism not caused by Graves' Disease (e.g., toxic adenoma or... [+6]

Read more
Status: Recruiting

Study of BHV-1400 in IgA Nephropathy

The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).

Participants needed: 20
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Biohaven Therapeutics Ltd.Updated: Jun 23, 2026Locations: 15
Eligibility criteria

Any secondary IgAN [+1]

Read more
Status: Not yet recruiting

A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy

The purpose of this study is to determine if BHV-1400 is effective and safe in the treatment of IgA Nephropathy. Participants will be randomized in a 2:1 ratio to receive either BHV-1400 or placebo.

Participants needed: 420
Trial details
Phase: Phase 3Age: 18-70Biological sex: AllType: InterventionalSponsor: Biohaven Therapeutics Ltd.Updated: Jun 11, 2026
Eligibility criteria

Diagnosis of IgAN as confirmed by renal biopsy conducted within 10 years prior t... [+6]

Any secondary IgAN as defined by the Investigator; secondary IgAN can be associa... [+4]

Read more
Status: Recruiting

Study of BHV-1300 in Graves' Disease

The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.

Participants needed: 15
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Biohaven Therapeutics Ltd.Updated: May 22, 2026Locations: 17
Eligibility criteria

History of hyperthyroidism not caused by Graves' Disease (e.g., toxic adenoma or... [+1]

Read more
Status: Recruiting

A Phase 1 Study of BHV-1530 in Advanced Solid Tumors

This is a Phase 1, first in human (FIH), open-label, multicenter study of BHV-1530 in adult participants with advanced or metastatic solid tumors.

Participants needed: 95
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Biohaven Therapeutics Ltd.Updated: May 13, 2026Locations: 13
Eligibility criteria

Signed, written Independent Ethics Committee (IEC)/Institutional Review Board (I... [+18]

Prior treatment with antibody drug conjugate (ADC) with a topoisomerase-I inhibi... [+25]

Read more
Status: Recruiting

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.

Participants needed: 390
Trial details
Phase: Phase 2, Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Biohaven Therapeutics Ltd.Updated: May 1, 2026Locations: 124
Eligibility criteria

Male and Female participants 18 to 75 years of age at time of consent. [+4]

History of status epilepticus (convulsive status epilepticus for > 5 minutes or... [+5]

Read more
Status: Recruiting

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.

Participants needed: 500
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Biohaven Therapeutics Ltd.Updated: Mar 11, 2026Locations: 17
Eligibility criteria

Male or female participants aged ≥18 years. [+15]

Women who are pregnant or lactating. [+15]

Read more
Status: Recruiting

A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease.

Participants needed: 550
Trial details
Phase: Phase 2, Phase 3Age: 40-85Biological sex: AllType: InterventionalSponsor: Biohaven Therapeutics Ltd.Updated: Jan 14, 2026Locations: 15
Eligibility criteria

Male or female participants 40 to 85 years of age, inclusive, at the time of inf... [+2]

Medical history indicating a Parkinsonian syndrome other than idiopathic PD, inc... [+4]

Read more